October 4, 2017 08:27 AM EDT

What failure? Catabasis shares soar after execs tout open-label data, PhIII plans

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

Lower attendance at cell and gene therapy conference mirrors challenged industry

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure